Announcement PDF IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES H1 2026 Results Webinar 26 August 2026 Forward looking statements This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors. 2 Large potential upside for shareholders is enabled by financial strength 3 *Rett and Fragile X syndromes are licensed to Acadia, with same economics to Neuren as trofinetide; Neuren retains worldwide rights to all other indications Phelan-McDermid syndrome (PMS) Pitt Hopkins syndrome (PTHS) Hypoxic Ischemic Encephalopathy (HIE) Angelman syndrome, Prader-Willi Syndrome, SYNGAP1, Rett syndrome (Acadia)*, Fragile X syndrome (Acadia)* NNZ-2591 2 indications prioritised for maximum commercial impact Long-term income growth from DAYBUE® (trofinetide)1 A$543m income from DAYBUE since launch in 2023 A$287 million cash as at 30 Jun 2026 1 Refer to www.acadia.com for DAYBUE (trofinetide) US prescribing and important safety information. Trofinetide is approved in the EU, Canada and Israel. Trofinetide is not approved in Australia 2 NNZ-2591 is an investigational medicine and is currently not approved for sale in any country Optimising total shareholder return with first-ever dividend program 4 Dividend program anchored to growing royalty income: • Semi-annual payment • Targeting payout ratio of 70 – 100% of the after-tax amount of royalty income less corporate and administrative costs (“Available Pool”) • Franked to max extent possible Declared interim dividend of 15c per share: • Fully franked • Representing 90% of H1 26 Available Pool • To be paid on 7 Oct 2026 A$m unless otherwise stated H1 2026 actual Full year 2026 estimates Royalty income US$m 23.3 52.6-56.2 AUD/USD exchange rate 0.702 0.70 Royalty income 33.2 75.1-80.3 Corporate & admin (3.0) (6.6) Net total before tax 30.2 68.5-73.7 Applicable tax @30% (9.0) (20.6-22.1) Available Pool 21.1 48.0-51.6 Payout ratio 90% Payout Amount 19.0 Dividend per share A$ 0.15 H1 2026 highlights 5 29 2.3 15.4 16.0 20.8 18.1 24.2 23.3 33 1H23 2H23 1H24 2H24 1H25 2H25 1H26 2H26E* Royalty income to Neuren US$ million * Range estimates based on full year 2026 royalty income estimates of US$53 – 56 million assuming Acadia meets its full year 2026 DAYBUE net sales guidance of US$480 – 510 million, less H1 26 actual royalty income of US$23.3 million CY26E US$53-56m CY25 US$42m CY24 US$37m CY23 US$18m On track for record FY 26 royalty income US$53-56m, with US$23.3m already earned in H1 26 H1 26 R&D investment of A$27.4mdriven by the expected progression of the Koala Phase 3 study in PMS Modest corporate & admin cost of A$3.0m for H1 26, fully offset by interest income of A$5.6m Strong balance sheet with A$287m cash & short-term investments at 30 Jun 2026 All NNZ-2591 programs are fully funded 6 Milestones achieved since Jan 2026 Q1 2026 Q2 2026 FDA feedback on PTHS and HIE Q3 2026 PMS Phase 2 published in Neurology Genetics Acadia request CHMP re- examination following negative opinion 1st patient dosed in 13-week placebo- controlled Koala Phase 3 study STIX limited launch in the US STIX broadly available in the US CHMP recommended DAYBU’s approval in EU after re-examination PMSF family conference presented by Neuren Published study supported by Neuren estimating the prevalence of PMS to be 1 in 7,300 people DAYBUE approved in Israel Growing sales in the US and through global named patient programs Koala active trial sites expanded from 2 to 15; 8 sites now active for open label extension (OLE) PRV program reauthorized by US Congress Acadia upgraded CY26 DAYBUE guidance 1st patient enrolled in Koala OLE after completing placebo-controlled study Delphi expert consensus recommended DAYBUE as standard of care for Rett in the US EC approval of DAYBU DAYBUE (trofinetide) 1 NNZ-2591 (ercanetide) 2 1 Refer to www.acadia.com for DAYBUE (trofinetide) US prescribing and important safety information. Trofinetide is approved in the EU, Canada and Israel. Trofinetide is not approved in Australia 2 NNZ-2591 is an investigational medicine and is currently not approved for sale in any country DAYBUE (trofinetide) Exclusively licensed to Acadia Pharmaceuticals globally 7 Strong DAYBUE sales momentum driving sustainable royalty growth 8 Refer to www.acadia.com for DAYBUE (trofinetide) US prescribing and important safety information. Trofinetide is approved in the EU, Canada and Israel. Trofinetide is not approved in Australia * Full year estimates based on Acadia full year 2026 DAYBUE Net Sales Guidance of US$480-510m 1 Prange EO, Beisang A, Pehlivan D, et al. Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. Ann Child Neurol. 2026; 4:38-51 Record quarterly sales in Q2 and upgraded 2026 guidance by Acadia Delphi expert consensus panel recommended DAYBUE as part of the standard of care for eligible patients with Rett syndrome1 DAYBUE STIX accelerating engagement with new and returning patients 8.5 10.4 9.6 12.9 53 18 37 42 56 CY2023 CY2024 CY2025 CY2026E* Royalty to Neuren (US$m) 85 101 96 125 480 177 348 391 510 CY2023 (Apr -Dec) CY2024 CY2025 CY2026E Acadia Guidance DAYBUE Net Sales (US$m) +23–30% + 24–33% Q2 Q2 Q1 Q1 Approved Aug 2026 9,000 - 12,000 Rett patients1 Phase 3 results Sep–Nov 2026 1,000 Rett patients1 Approved Mar 2023 6,000 - 9,000 Rett patients1 Long term growth opportunity through global expansion 9 Tiered Royalty Rates (% of net sales)3 1 Acadia estimates 2 Each milestone payment is payable once only 3 Royalty rates payable on the portion of annual net sales that fall within the applicable range Future Sales Milestones2 Future Development Milestones2 US$35m following 1st commercial sale in Europe US$15m following 1st commercial sale in Japan Net Sales in a CY US$m ≥US$500m 50 ≥US$750m 100 ≥US$1bn 150 Annual Net Sales Rates ≤US$250m 10% >US$250m, ≤US$500m 12% >US$500m, ≤US$750m 14% >US$750m 15% Up to US$170m on achievement of escalating annual net sales thresholds Up to US$110m on achievement of escalating annual net sales thresholds Mid-teens to low-20s % of net sales Mid-teens to low-20s % of net sales NNZ-2591 (ercanetide) 10 Neuren is leading the development of a first treatment for Phelan- McDermid syndrome (PMS) 11 The Voice of the Patient…..1 “PMS has an overwhelming unmet medical need. There are no FDA approved treatments for PMS despite its severely debilitating manifestations. Parents and caregivers are open to trying almost anything to try to relieve their child’s suffering; most have tried an incredibly high number of treatments and approaches for symptom management, with very little success.” NNZ-2591 (ercanetide) program ✓ Orphan Drug designation (US and EU) ✓ Rare Pediatric Disease designation (US) ✓ Meaningful improvements rated by clinicians and caregivers in open-label Phase 2 trial2 ✓ Alignment with FDA on single Phase 3 trial design and endpoints to support a New Drug Application ✓ Fast Track designation (US) ✓ Koala Phase 3 trial enrolling in US and Canada NNZ-2591 is an investigational medicine and is currently not approved for sale in any country 1 Excerpts from Voice of the Patient Report of Externally-Led Patient-Focused Drug Development Meeting Nov 2022 2 NEU-2591-PMS-001: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Phelan- McDermid Syndrome - 13 weeks treatment of patients age 3-12 years at 4 US sites Developmental delay/intellectual impairment (lack of safety awareness) and communication issues are the most troublesome concerns. Improved cognitive functioning and improved communication are the most desired outcomes. “PMS has severe quality of life impacts on those living with the disease, as well as on parents and siblings. Most activities of daily life, including communicating needs or wants, self-care (bathing, dressing, toileting) and socializing with peers/siblings are affected. Most individuals living with PMS rely on their parents and caregivers for all their daily needs, and many require 24-hour care.” 12 NNZ-2591 Placebo 160 80 80 Double-blind, 13 weeks NNZ-2591 Open label, 12 months Randomised 1:1 giving estimated 95% power for each co- primary endpoint Koala - the first ever Phase 3 trial in PMS Screening 4 - 6 weeks Same age range (3-12) and same length of treatment (13 weeks) as Phase 2 Target dosing equivalent to dose tested in Phase 21 ~20 trial sites, mostly in US Program fully funded from existing cash NNZ-2591 is an investigational medicine and is currently not approved for sale in any country 1 12.5 mg/kg per day in Phase 3 vs 12 mg/kg in Phase 2, and titration period two weeks in Phase 3 vs six weeks in Phase 2 Alignment with FDA on single Phase 3 trial design and endpoints to support a NDA 13 Neuren’s leadership in science and community for PMS Recent published study supported by Neuren estimating the prevalence of PMS to be 1 in 7,300 people (~39,000 in North America1) Honoured to support and participate in the biannual PMSF Family Conference as the Presenting Sponsor Koala Phase 3 study2 continues to gain momentum 15 trial sites in US/Canada activated 100+ patients referred to sites or await site activation 8 sites activated in OLE for completers of 13-weeks study First patient from Phase 2 study enrolled in OLE NNZ-2591 is an investigational medicine and is currently not approved for sale in any country 1 Estimates based on United Nations population data 2025, derived by applying the estimated prevalence rate to the populations under 60 years 2 Koala is a randomised, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of NNZ-2591 for 13 weeks in approximately 160 children aged 3 to 12 years and a 52- week open-label extension study 14 A milestone-rich roadmap Q3 2026 Q4 2026 2027 JP trial top-line results DAYBUE (trofinetide) 1 NNZ-2591 (ercanetide) 2 Commercial launch in Germany Acadia Q3 26 results US$35m 1st EU commercial sale milestone payment JP NDA submission Acadia Q4 26 results Commencement of juvenile animal toxicity study to support HIE IND FDA meeting to align PTHS Phase 3 study IND application and FDA meeting for HIE Periodic updates on Koala progress PTHS Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting with the FDA 1 Refer to www.acadia.com for DAYBUE (trofinetide) US prescribing and important safety information. Trofinetide is approved in the EU, Canada and Israel. Trofinetide is not approved in Australia 2 NNZ-2591 is an investigational medicine and is currently not approved for sale in any country CONTACT investorrelations@neurenpharma.com 15